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Aortic Valve Replacement with a Conventional 
Stented Bioprosthesis versus Sutureless 
Bioprosthesis: a Study of 763 Patients
Syed Saleem Mujtaba1, MD; Simon M. Ledingham1, MD; Asif Raza Shah1, MD; Thasee Pillay1, MD; Stephan Schueler1, 
MD, PhD; Stephen Clark1, MD
Abstract
Objective: The aim of this retrospective study was to compare 
early postoperative outcomes after aortic valve replacement 
(AVR) with sutureless bioprostheses and conventional stented 
bioprostheses implanted through median sternotomy. 
Methods: From January 2011 to December 2016, 763 patients 
underwent aortic valve replacement with bioprostheses; of these, 
139 received a Perceval S sutureless valve (Group A) and 624 received 
a Perimount Magna Ease valve (Group B). These groups were further 
divided into A1 (isolated Perceval AVR), A2 (Perceval AVR with 
coronary artery bypass grafting [CABG]), B1 (isolated conventional 
stented bioprosthesis), and B2 (conventional stented bioprosthesis 
+ CABG). 
Results: Patients in Group A were older (mean 74 years vs. 71 
years; P<0.0001), predominantly women (53% vs. 32%; P<0.0001), 
had a higher logistic EuroSCORE (3.26 vs. 2.43; P<0.001), more 
preoperative atrial fibrillation (20% vs. 13%; P=0.03), and had a 
lower reopening rate for bleeding (2.1% vs. 6.7%; P=0.04). Compared 
to Group B1, Group A1 had shorter cross-clamp (mean 40 min vs. 
57 min; P≤0.0001) and bypass times (mean 63 min vs. mean 80 min; 
P=0.02), and they bled less postoperatively (mean 295 ml vs. mean 
393 ml; P=0.002). The mean gradient across Perceval valve was 12.5 
mmHg while its effective orifice area was 1.5 cm2. 
Conclusion: In our retrospective study of 763 patients, sutureless 
valve group patients are older, mostly women, more symptomatic 
preoperatively, and have higher logistic EuroSCORE. They have 
shorter cross-clamp and bypass times, less postoperative bleeding, 
and reduced incidence of reopening. Further studies are needed to 
evaluate the clinical benefits in short, mid, and long-terms.
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Abbreviations, acronyms & symbols
AF
AVR
CABG
CBP
CCC
CPB
EOA
ICU
LVEF
MPG
NASCA
NICOR
PPM
SCTS
TAVI
 = Atrial fibrillation
 = Aortic valve replacement
 = Coronary artery bypass grafting 
 = Cumulative bypass 
 = Cumulative cross-clamp
 = Cardiopulmonary bypass
 = Effective orifice area 
 = Intensive care unit
 = Left ventricular ejection fraction
 = Mean pressure gradients
 = National Adult Cardiac Surgery Audit
 = National Institute for Cardiovascular Outcomes Research
 = Patient prosthesis mismatch
 = Society for Cardiothoracic Surgeons
 = Transcatheter aortic valve implantation
INTRODUCTION
Aortic valve replacement (AVR) is the treatment of choice for 
aortic valve stenosis when it is a symptomatic severe aortic stenosis 
(≤1 cm2/m2) or an asymptomatic with left ventricular dysfunction 
or combined with other cardiac surgery procedure[1]. Surgical 
AVR still represents the gold standard treatment in patients 
with severe aortic valve stenosis[2]. Owing to the increasing 
age of the patient population in Western world, there has been 
an increase in the prevalence of patients with valvular heart 
disease eligible for AVR[3]. A majority of these geriatric patients 
are females of small stature with corresponding small aortic 
roots. It has been suggested that patient prosthesis mismatch 
(PPM) may be associated with less regression of left ventricular 
hypertrophy and lower survival[4]. Given the increasing number 
of comorbidities and increasing age of patients, a tendency has 
emerged to use biological valve implants thus avoiding the need 
for long-term anticoagulation therapy. Although the concept of 
transcatheter aortic valve implantation (TAVI) appears attractive, 
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managed by National Institute for Cardiovascular Outcomes 
Research (NICOR), with clinical direction and strategy provided 
by the Society for Cardiothoracic Surgeons (SCTS) and the Project 
Board. Analysis was performed using MS Excel. Numerical values 
were compared using an independent t-test, with a two-tailed 
distribution assuming unequal variances. Categorical variables 
were compared using Chi-squared χ2 analysis.
Surgical Technique
After a full median sternotomy, standard CPB was established 
by cannulation of the ascending aorta and the right atrium. The 
heart was vented through the right superior pulmonary vein or 
the main pulmonary artery. Antegrade cold blood cardioplegia 
was used for myocardial protection. Continuous carbon dioxide 
insufflation was used routinely after sternotomy until closure of the 
aortotomy. In combined cases, distal end coronary anastomoses 
were performed before opening the aorta, and proximal end was 
performed after the cross-clamp is taken off, with the side biter on.
Perceval Valve
The ascending aorta was incised transversally 1.5 cm 
above the sinotubular junction in order to leave a free edge for 
closure of the aortotomy after implantation of the device. The 
aortic valve was removed, and the annulus was decalcified in 
the usual fashion. The aortic orifice was measured with valve 
manufacturer’s sizers.
Three 4/0 polypropylene guiding sutures were passed 
through the nadir of the aortic annulus. An appropriately sized 
prosthesis was collapsed on a side table and placed into the 
delivery system.
The three guiding sutures were passed through the three 
guides arising from the annular ring of the prosthesis, which 
was consequently seated on the fully debrided annulus. Once 
the delivery system was in position, the valve was deployed by 
turning the release screw and leaving the valve in place. The 
delivery system and guiding sutures were then removed. The 
field was rinsed with warm saline, and the prosthesis was dilated 
at four atmospheres for 30 seconds. 
Perimount Magna Valve
A transverse aortotomy was made 2 cm above the right 
coronary artery. Semicontinuous 2/0 Prolene sutures or 
interrupted non-pledgeted Ethibond sutures were used to stitch 
the aortic valve to the annulus. After closure of the aortotomy, 
transesophageal echocardiography was performed to assess the 
correct implantation of the prosthesis and the presence of any 
paravalvular leak.
RESULTS
Preoperative patient characteristics are outlined in Tables 1 
and 2.
There was no difference between Groups A and B in history 
of preoperative renal impairment or pulmonary disease. Group 
A had more female patients (A=53% vs. B=32%; P<0.0001) 
and patients with hypertension (76% vs. 67%; P=0.03) and 
the calcified aortic valve is not removed during this procedure. 
Therefore paravalvular leakage remains an important issue with 
this technique[5]. Other important concerns are access site-
related problems and device malpositioning.
The recent introduction of sutureless bioprostheses may 
offer an additional tool in the therapeutic armamentarium as 
these valves do not need to be sutured into place, resulting in 
shorter cross-clamp and cardiopulmonary bypass (CPB) times 
which may be beneficial in older patients with comorbid 
conditions. Moreover, due to the absence of a sewing ring, these 
valves exhibit favourable hemodynamic properties. Excellent 
outcomes have been demonstrated with sutureless AVR in 
minimally invasive surgical setting[6].
This study provides a comparison between the sutureless 
Perceval valve and the conventional stented sutured biological 
valve in an attempt to better define the role of sutureless AVR in 
the treatment of critical aortic valve stenosis.
METHODS
This is a retrospective, observational cohort study of 
consecutive patients with aortic valve disease who underwent 
AVR with sutureless and conventional bioprostheses between 
January 2011 and December 2016. During this period, 763 
patients underwent AVR with bioprostheses. Of these, 139 
received a Perceval sutureless valve (Sorin, Saluggia, Italy) (Group 
A) and 624 received a Carpentier-Edwards Perimount Magna 
Ease aortic valve (Edwards Lifesciences, Irvine, CA, USA) (Group 
B). Group A was further divided into isolated Perceval valve 
(A1) and Perceval valve combined with coronary artery bypass 
grafting (CABG) (A2). Similarly, Group B was further divided into 
isolated Perimount magna ease (B1) and Perimount magna ease 
with CABG (B2). All patients were operated upon by one of six 
different surgeons at our institution. Preoperative characteristics 
and postoperative data of all these patients were studied 
retrospectively and Group A was compared with Group B.
If the patients had indications for AVR and wished to have a 
biological valve, they were given a Perceval valve, provided they 
had no contraindications. Although the age range of our patients 
for Perceval valve is 47-86 years old, very few young patients 
(<60 years old) had Perceval valve, as it is evident from mean and 
median age. Most of the young patients had a combination of 
bicuspid and early degenerative aortic valve stenosis. We totally 
respected our patient’s wishes, if they preferred to have tissue 
valve, we provided them with Perceval valve, as long as they 
fulfilled the criterion.
For Perceval valve cases, congenital pure bicuspid aortic 
valves (Sievers type 0) with abnormal sinotubular junction 
(annulus ratio or aortic annulus greater than 27 mm or lesser than 
19 mm) were excluded. Patients with ascending aortic aneurysm 
or dissection, emergency intervention, acute endocarditis, redo 
cases and other combined cases (beside AVR+CABG) were also 
excluded from both groups.
Statistical Analysis
The data used in this analysis were extracted from National 
Adult Cardiac Surgery Audit (NASCA) database. This audit is 
Mujtaba SS, et al. - Perceval versus Conventional Biological Valve
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Table 1. Preoperative summary.
Group A Group B 
Chi-squared 
test
n =139 % n =624 % P
Gender (M/F) 65/74 47/53 459/215 68/32 <0.0001
Procedure types 
Isolated aortic valve replacement 92 66 426 68
AVR+CABG or other procedures 47 34 198 32
History of cigarette smoking 83 60 410 66 0.18
History of hypertension 106 76 418 67 0.03
Renal disease at time of surgery 1 0.70 5 0.80 0.92
History of pulmonary disease, i.e. COPD, asthma 32 23.02 126 20.19 0.46
History of neurological disease, i.e. TIA, CVA 25 18 71 11 0.03
Angina status before surgery 
0. No angina 49 35 316 51
1. No limitation of physical activity 33 24 127 20
2. Slight limitation of ordinary activity 29 21 112 18
3. Marked limitation of ordinary physical activity 25 18 56 9
4. Symptoms at rest or minimal activity 3 2 13 2
Angina symptoms 90 64.7 308 49.4 0.001
Dyspnoea status before surgery 
1. No limitation of physical activity 12 8.70 122 19.55
2. Slight limitation of ordinary physical activity 53 38 264 42
3. Marked limitation of ordinary physical activity 71 51 220 35
4. Symptoms at rest or minimal activity 3 2 18 3
Dyspnoea symptoms 127 91.4 502 80.4 0.002
History of diabetes mellitus 30 22 120 19 0.53
Preoperative heart rhythm 
0. Sinus rhythm 109 78 530 84.94
1. Atrial fibrillation/flutter 28 20 82 13 0.03
2. Complete heart block/pacing 2 1.40 3 0 0.21
3. Other abnormal rhythm 0 0 4 1
Ejection fraction category 
1. Good (LVEF > 50%) 111 80 498 79.8
2. Fair (LVEF 30-50%) 22 16 85 14 0.50
3. Poor (LVEF < 30%) 6 4 40 6 0.35
AVR=aortic valve replacement; CABG=coronary artery bypass grafting; COPD=chronic obstructive pulmonary disease; 
CVA=cerebrovascular accident; F=female; LVEF=left ventricular ejection fraction; M=male; TIA=transient ischemic attack
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bypass times (range 25-172 min, mean 63 min vs. range 19-285 
min, mean 80 min; P=0.002) were shorter in the isolated Perceval 
valve group (Group A1) compared to the isolated conventional 
valve group (Group B1). When A2 (Perceval valve + CABG) was 
compared with B2 (conventional valve + CABG), A2 had a shorter 
cross-clamp time (range 28-127 min, mean 68 min vs. range 40-
177, mean 78 min; P=0.02), but no significant difference was 
found in bypass time (range 38-403 min, mean 107 min vs. range 
60-280 min, mean 112 min; P=0.51).
neurological dysfunction (18% vs. 11%; P=0.03). Also, Group A 
had more patients with angina (90% vs. 49%; P=0.001), dyspnoea 
(91% vs. 80%; P=0.002), and preoperative atrial fibrillation (AF) 
(20% vs. 13%; P=0.03). In Group A, patients were older (range: 47-
86 years old, mean 74 vs. range 34-91, mean 71; P=0.0001) and 
had a higher logistic EuroSCORE (3.26 vs. 2.43; P=0.001). 
Intraoperative and early postoperative variables are 
summarized in Tables 3 and 4. Cross-clamp (range 21-114 min, 
mean 40 min vs. range 24-164 min, mean 57 min; P<0.0001) and 
Table 2. Preoperative summary (comparison between Groups A and B).
Group A 
range
Mean Median
Group B 
range
Mean Median P
Age of patients at time of procedure 47-86 74.3 75.5 34-91 71.74 73 <0.0001
Logistic EuroSCORE comparison 0.53-18.886 3.26 2.46 0-16.527 2.43 1.84 0.001
Height (cm) 140-185 162 162 138-190 166.30 167 <0.0001
Weight (kg) 40.3-158 79 74 44.9-181.6 81.47 80 0.13
Table 3. Intraoperative and early postoperative summary of isolated AVR.
Intraoperative and early 
postoperative summary
Isolated AVR: 
Perceval 
Isolated AVR: 
Perimount
Isolated 
valve
Group A1 
n=92
Group B1 
n=426
Group A
Range Mean Median Range Mean Median P
Cumulative cross-clamp time (min) 21-114 40 37 24-164 56.6 52 <0.0001
Cumulative bypass time 25-172 63 59 19-285 80.1 76 0.02
Postoperative blood loss at 12 hours 50-2000 295 225 100-2725 393.3 300 0.002
ICU stay in days 1-32 3.4 1 1-34 2.4 1 0.07
AVR=aortic valve replacement; ICU=intensive care unit
Table 4. Intraoperative and early postoperative summary of AVR+CABG.
Intraoperative and early 
postoperative summary
Perceval
AVR+CABG
Perimount
AVR+CABG
Group A2 
n=47
Group B2 
n=198
Range Mean Median Range Mean Median P
Cumulative cross-clamp time (min) 28-127 68 61 40-177 78.3 72 0.02
Cumulative bypass time 38-403 107 87 60-280 112.7 107 0.51
Postoperative blood loss at 12 hours 50-1200 457 400 100-2825 484.9 380 0.58
ICU stay in days 1-93 6.8 3 1-34 3.2 1 0.09
AVR=aortic valve replacement; CABG=coronary artery bypass grafting; ICU=intensive care unit
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Table 5. Postoperative summary (comparison between Groups A and B).
Postoperative summary
Group A: 
Perceval 
Group B: 
Perimount
n = 139 % n = 624 % P
Reoperation for bleeding, tamponade, or valvular problems 3 2.10% 42 6.73% 0.04
Sternal wound infection 2/139 1.43% 14 2.24% 0.55
New postoperative neurological dysfunction 4/139 2.80% 9 1.44% 0.24
New HF/dialysis postoperatively 5/139 3.60% 37 5.93% 0.28
Patient status at discharge (mortality) 3/139 2.10% 15 2.40% 0.86
SIRS 21/139 15% 111 18% 0.45
Arrhythmias
None 88 63% 342 55%
AF/Flutter 46 33% 258 41% 0.07
Permanent pacemaker 5 3.60% 12 1.92% 0.23
AF=atrial fibrillation; HF=haemofiltration; SIRS=systemic inflammatory response syndrome
The mean gradient across Perceval valve was found to be 
higher for the smaller valves and lower for the larger valves. It 
ranges from 6-18 mmHg and its mean value was 12.5 mmHg. 
Similarly, its effective orifice area (EOA) varies according to the 
valve sizes, but its mean value was 1.5 cm2.
The incidence of complications over the early postoperative 
course is depicted in Table 5. In this study, we used first 12 hours 
drainage, as traditionally first 12 hours drainage is recorded in 
NASCA database and it is easy to retrieve. Most of the time it is 
the total drainage, but not always.
Isolated Perceval group (Group A1) had less bleeding in first 12 
hours compared to the isolated conventional valve group (Group 
B1) (range 50-2000 ml, mean 295 ml vs. range 100-2725 ml, mean 
393 ml; P=0.002), but there was no significant difference when 
A2 (Perceval valve + CABG) was compared with B2 (conventional 
valve + CABG) (range 50-1200 ml, mean 457 ml vs. range 100-2825 
ml, mean 485 ml;  = 0.58). There were more patients reoperated 
for bleeding or tamponade in Group B than in Group A (2.1% vs. 
6.7%; P=0.04). There was no significant difference in postoperative 
neurological dysfunction, renal impairment, AF, permanent 
pacemaker requirement, or mortality.
DISCUSSION
New scientific and technologic achievements have allowed 
a continuous decrease in mortality and morbidity for AVR, in 
spite of the more complex and elderly patients being referred 
for surgery. The primary goal of AVR is to alleviate the pressure 
overload on the left ventricle and to allow regression as well 
as remodelling of the left ventricular mass. A smaller-sized 
prosthetic valve may result in so-called PPM. 
Therefore, different options have been proposed for 
patients with small aortic root presenting for AVR, i.e.: stentless 
valves, aortic root enlargement, and even complete aortic root 
replacement. However, all these options are technically more 
complex and take a longer operating time. Hence, they have not 
been popular with surgeons.
Magovern et al.[7] introduced the concept of sutureless 
aortic valve in the 1960s with a ball-cage-type mechanical 
valve for sutureless implantation. It had its own disadvantages, 
i.e.: high incidence of paravalvular leaks, bulky size and it was 
not suitable for small annuli[8]. There was a high incidence of 
thromboembolism (42%) and reoperation (16%). This valve 
continued to be used however until 1980.
The introduction of sutureless bioprostheses in the last 
decade offered a unique therapeutic opportunity given the 
possibility to potentially yield the advantages of a traditional 
surgical valve replacement (as the native valve can be fully excised) 
and a transcatheter approach (as it can be rapidly implanted). 
Moreover, aortic cross-clamp and total cardiopulmonary times 
are also reduced. 
Therefore, the aim of the current study was to analyse and 
compare the early clinical outcomes of conventional AVR with a 
sutureless valve prosthesis.
Shrestha et al.[9] highlighted the advantages of sutureless 
valves for geriatric patients with small aortic roots. They showed 
that Perceval sutureless valve implants are associated with shorter 
cross-clamp and CPB times compared to conventional biological 
valves, even though most of these patients were operated on via 
minimally invasive access. 
Moreover, due to the absence of a sewing ring, these valves 
have favourable EOA and haemodynamics for any given size. This 
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via ministernotomy. Gilmanov et al.[10] implanted Perceval valve 
through right mini-thoracotomy and their median CCC & CBP 
times were 56 and 90 minutes, respectively. All these studies, 
including ours, showed shorter CCC & CBP times compared to 
conventional biological valve and this difference was statistically 
significant. Prolonged aortic cross-clamp time significantly 
correlates with major postoperative morbidity and mortality 
in both low- and high-risk cardiac surgery patients. This effect 
increases with prolonged cross-clamp time[13]. Al-Sarraf et al.[13] 
have shown that by using cross-clamp time as a continuous 
variable, an incremental increase of 1 min interval in cross-clamp 
time was associated with a 2% increase in mortality in both low- 
and high-risk groups. In addition, high-risk patient populations 
such as those with diabetes or depressed left ventricular ejection 
fraction (LVEF) were found to benefit the most from a reduction 
in aortic cross-clamp time[14].
Our mean pressure gradients (MPG) and EOA were 
comparable with the values reported in literature for Perceval 
valves. Folliguet et al.[15] (10.4±4.3 mmHg), Santarpino et al.[16] 
(13.4±2.8 mmHg), Flameng et al.[17] (11 range 5-28 mmHg), 
D’Onofrio et al.[18] (10.95±3.72 mmHg), and the Cavalier Trial[19] 
(10.24 mmHg) reported pre-discharge MPG, while Shrestha et 
al.[9] discussed 12-month follow-up data (10±5 mmHg). Our EOA 
was also compatible with the Cavalier study results[19] (1.46 cm2). 
In our study, the Perceval group includes older patients, 
more women, and more comorbidities, as evident by a higher 
logistic EuroSCORE. Although their postoperative drainage is 
lower, because of more comorbidities and for being sicker, 
they spent more time in ICU, but this difference was not 
statistically significant. Moreover, higher logistic EuroSCORE 
was not reflected in a higher mortality, as the difference 
was not statistically significant. Maybe the factor of a higher 
comorbidity was buffered by a shorter cross-clamp time.
Limitations
This study carries all the limitations that a retrospective 
analysis design implies. Patients in the sutureless group were 
operated upon more recently than the majority of those receiving 
conventional valves. Propensity matching is not performed 
which could have provided more accurate comparison.
CONCLUSION
Despite the limits of its retrospective design, this study 
represents the largest single-center comparison between 
Perceval sutureless valve and conventional bioprostheses for AVR. 
We observed that in our study of 763 patients, sutureless valve 
group patients are older, mostly women, more symptomatic, and 
have higher logistic EuroSCORE. Despite this, those operated on 
with the Perceval valve showed shorter cross-clamp and bypass 
times, less postoperative bleeding, and a reduced incidence of 
reopening. Further studies are needed to evaluate the clinical 
benefits in short, mid and long-terms.
may potentially result in better haemodynamics even without 
root enlargement in small annular sizes.
Gilmanov et al.[10] reviewed 515 patients undergoing 
primary AVR through a right anterior mini-thoracotomy (269 
conventional vs. 246 sutureless prostheses). They showed that 
the use of Perceval sutureless valve had shorter cross-clamp, 
bypass, and mechanical ventilation times. Pollari et al.[11] studied 
566 patients who underwent AVR with bioprostheses. Of these, 
166 received a sutureless valve and 400 received a stented valve. 
Aortic cross-clamp and CPB times were significantly shorter in 
the sutureless group. Patients from the sutureless group required 
blood transfusion less frequently and had shorter intensive care 
unit (ICU) stay, hospital stay, and intubation time. 
A shorter procedural time in the sutureless group is 
associated with better clinical outcomes and reduced hospital 
costs. Dalén et al.[12] compared 182 patients who underwent 
a ministernotomy with a sutureless bioprosthesis and 383 
patients who had full sternotomy with a stented bioprosthesis. 
They concluded that sutureless bioprostheses were associated 
with shorter aortic cross-clamp and CPB times and less blood 
transfusion.
In our study, the Perceval valve group had lower incidence 
of total drainage and re-exploration rate. We think it happens 
because of a short bypass time. We have clearly shown that 
Perceval valve patients have shorter cross-clamp and bypass times 
and lower incidence of postoperative bleeding, but longer ICU 
stay (not statistically significant). We think that if these patients had 
had a traditional Perimount Magna Ease valve, they might have 
had a potentially longer ICU stay. It is only an assumption, but we 
need to do a randomised control trial to prove it.
Additionally, in our study, patients with isolated AVR with 
Perceval valve spent 3.4 days (mean) and 1 day (median) in ICU. 
Gilmanov et al.[10] observed the same ICU stay as 1 day (median). 
In other studies, ICU stay was not very different, i.e.: Shrestha et 
al.[9] (1.8±1.8 days), Pollari et al.[11] (2±1.2 days), and Dalén et al.[12] 
(2.4±2.4 days).
Our results correlated well with those from Shrestha et al.[9] 
and Gilmanov et al.[10], although they operated on small aortic 
root and through right mini-thoracotomy, respectively. Pollari et 
al.[11] also had shorter cross-clamp and bypass times like us, but 
contrary to our study, their ICU stay was shorter in the Perceval 
group. Our results also matched those from Dalén et al.[12], but 
they showed less blood transfusion, which we did not.
Our cumulative cross-clamp (CCC) and cumulative bypass 
(CBP) times for isolated AVR with Perceval valve match quite 
well with those from previous studies. Our mean CCC & CBP 
times are 40 and 63 minutes, respectively. The same times for 
Shrestha et al.[9] were 30.1±9.0/58.7±20.9 minutes, although 
most of these patients were operated on via minimally invasive 
access. Pollari et al.[11] reported CCC & CBP times of 35±12 and 
71±11 minutes, respectively, but they also included some redo 
cases. CCC & CBP times for Dalen et al.[12] were 40±15 and 69±20 
minutes, respectively, although they performed their surgeries 
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